2,872
Views
15
CrossRef citations to date
0
Altmetric
Research Paper

A physico-chemical assessment of the thermal stability of pneumococcal conjugate vaccine components

, , , &
Pages 2744-2753 | Received 16 Apr 2014, Accepted 23 Jun 2014, Published online: 17 Nov 2014

References

  • Straetemans M, Sanders EA, Veenhoven RH, Schilder AG, Damoiseaux RA, Zielhuis GA. Review of randomized controlled trials on pneumococcal vaccination for prevention of otitis media. Pediatr Infect Dis J 2003; 22:515-24; PMID:12799508; http://dx.doi.org/10.1097/01.inf.0000069763.08122.1c
  • O’Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, Kumar G, Parkinson A, Hu D, Hackell J, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362:355-61; PMID:12907008; http://dx.doi.org/10.1016/S0140-6736(03)14022-6
  • van Gils EJM, Veenhoven RH, Rodenburg GD, Hak E, Sanders EAM. Effect of 7-valent pneumococcal conjugate vaccine on nasopharyngeal carriage with Haemophilus influenzae and Moraxella catarrhalis in a randomized controlled trial. Vaccine 2011; 29:7595-8; PMID:21893151; http://dx.doi.org/10.1016/j.vaccine.2011.08.049
  • Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30:100-21; PMID:10619740; http://dx.doi.org/10.1086/313608
  • Ho MM, Bolgiano B, Corbel MJ. Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines. Vaccine 2000; 19:716-25; PMID:11115692; http://dx.doi.org/10.1016/S0264-410X(00)00261-9
  • Bolgiano B, Mawas F, Yost SE, Crane DT, Lemercinier X, Corbel MJ. Effect of physico-chemical modification on the immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM(197) conjugate vaccines. Vaccine 2001; 19:3189-200; PMID:11312015; http://dx.doi.org/10.1016/S0264-410X(01)00024-X
  • Ho MM, Mawas F, Bolgiano B, Lemercinier X, Crane DT, Huskisson R, Corbel MJ. Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines. Vaccine 2002; 20:3509-22; PMID:12297396; http://dx.doi.org/10.1016/S0264-410X(02)00342-0
  • Saydam M, Burkin K, Care R, Rigsby P, Bolgiano B, Mawas F. Immunogenicity and thermal stability of a combined vaccine against Haemophilus influenzae type b and Neisseria meningitidis serogroup C diseases. Vaccine 2010; 28:6228-34; PMID:20638457; http://dx.doi.org/10.1016/j.vaccine.2010.07.005
  • Munson RS Jr., Sasaki K. Protein D, a putative immunoglobulin D-binding protein produced by Haemophilus influenzae, is glycerophosphodiester phosphodiesterase. J Bacteriol 1993; 175:4569-71; PMID:8392514
  • Talaga P, Vialle S, Moreau M. Development of a high-performance anion-exchange chromatography with pulsed-amperometric detection based quantification assay for pneumococcal polysaccharides and conjugates. Vaccine 2002; 20:2474-84; PMID:12057602; http://dx.doi.org/10.1016/S0264-410X(02)00183-4
  • Lindberg B, Lindqvist B, Lönngren J, Powell DA. Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 1. Carbohydr Res 1980; 78:111-7; PMID:7351025; http://dx.doi.org/10.1016/S0008-6215(00)83664-2
  • Jones C, Currie F, Forster MJ. N.m.r. and conformational analysis of the capsular polysaccharide from Streptococcus pneumoniae type 4. Carbohydr Res 1991; 221:95-121; PMID:1667857; http://dx.doi.org/10.1016/0008-6215(91)80051-N
  • Jansson PE, Lindberg B, Lindquist U. Structural studies of the capsular polysaccharide from Streptococcus pneumoniae type 5. Carbohydr Res 1985; 140:101-10; PMID:4053092; http://dx.doi.org/10.1016/0008-6215(85)85053-9
  • Kenne L, Lindberg B, Madden JK. Structural studies of the capsular antigen from Streptococcus pneumoniae type 26. Carbohydr Res 1979; 73:175-82; PMID:38908; http://dx.doi.org/10.1016/S0008-6215(00)85487-7
  • Moreau M, Richards JC, Perry MB, Kniskern PJ. Application of high-resolution n.m.r. spectroscopy to the elucidation of the structure of the specific capsular polysaccharide of Streptococcus pneumoniae type 7F. Carbohydr Res 1988; 182:79-99; PMID:3149544; http://dx.doi.org/10.1016/0008-6215(88)84093-X
  • Perry MB, Daoust V, Carlo DJ. The specific capsular polysaccharide of Streptococcus pneumoniae type 9V. Can J Biochem 1981; 59:524-33; PMID:6271367; http://dx.doi.org/10.1139/o81-073
  • Lindberg B, Lönngren J, Powell DA. Structural studies on the specific type-14 pneumococcal polysaccharide. Carbohydr Res 1977; 58:177-86; PMID:21030; http://dx.doi.org/10.1016/S0008-6215(00)83413-8
  • Lugowski C, Jennings HJ. Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 18C (56). Carbohydr Res 1984; 131:119-29; PMID:6488199; http://dx.doi.org/10.1016/0008-6215(84)85409-9
  • Jennings HJ, Rosell K-G, Carlo DJ. Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 19 (19F). Can J Chem 1980; 58:1069-74; http://dx.doi.org/10.1139/v80-167
  • Richards JC, Perry MB. Structure of the specific capsular polysaccharide of Streptococcus pneumoniae type 23F (American type 23). Biochem Cell Biol 1988; 66:758-71; PMID:2846013; http://dx.doi.org/10.1139/o88-087
  • Janson H, Hedén LO, Grubb A, Ruan MR, Forsgren A. Protein D, an immunoglobulin D-binding protein of Haemophilus influenzae: cloning, nucleotide sequence, and expression in Escherichia coli. Infect Immun 1991; 59:119-25; PMID:1987023
  • Song XM, Forsgren A, Janson H. The gene encoding protein D (hpd) is highly conserved among Haemophilus influenzae type b and nontypeable strains. Infect Immun 1995; 63:696-9; PMID:7822043
  • Giannini G, Rappuoli R, Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 1984; 12:4063-9; PMID:6427753; http://dx.doi.org/10.1093/nar/12.10.4063
  • Xing DK, Crane DT, Bolgiano B, Corbel MJ, Jones C, Sesardic D. Physicochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro. Vaccine 1996; 14:1205-13; PMID:8961506; http://dx.doi.org/10.1016/S0264-410X(96)00032-1
  • Lee C-J, Lin K-T. Studies on vaccine control and immunogenicity of polysaccharides of Streptococcus pneumoniae. Rev Infect Dis 1981; 3(Suppl):S51-60; PMID:6169130; http://dx.doi.org/10.1093/clinids/3.Supplement_1.S51
  • Sweeney JA, Sumner JS, Hennessey JP Jr. Simultaneous evaluation of molecular size and antigenic stability of PNEUMOVAX 23, a multivalent pneumococcal polysaccharide vaccine. Dev Biol (Basel) 2000; 103:11-26; PMID:11214229
  • MacNair JE, Desai T, Teyral J, Abeygunawardana C, Hennessey JP Jr. Alignment of absolute and relative molecular size specifications for a polyvalent pneumococcal polysaccharide vaccine (PNEUMOVAX 23). Biologicals 2005; 33:49-58; PMID:15713556; http://dx.doi.org/10.1016/j.biologicals.2004.11.002
  • Abeygunawardana C, Williams TC, Sumner JS, Hennessey JP Jr. Development and validation of an NMR-based identity assay for bacterial polysaccharides. Anal Biochem 2000; 279:226-40; PMID:10706792; http://dx.doi.org/10.1006/abio.1999.4470
  • Gessner BD, Mueller JE, Yaro S. African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults. BMC Infect Dis 2010; 10:22; http://www.biomedical.com/1471-2334/10/22; PMID:20146815; http://dx.doi.org/10.1186/1471-2334-10-22.
  • Zon G, Szu SC, Egan W, Robbins JD, Robbins JB. Hydrolytic stability of pneumococcal group 6 (type 6A and 6B) capsular polysaccharides. Infect Immun 1982; 37:89-103; PMID:7107011
  • Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène J-P, Lommel P, Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28(Suppl):S66-76
  • Nurkka A, Joensuu J, Henckaerts I, Peeters P, Poolman J, Kilpi T, Käyhty H. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23:1008-14; PMID:15545855; http://dx.doi.org/10.1097/01.inf.0000143640.03214.18
  • Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367:740-8; PMID:16517274; http://dx.doi.org/10.1016/S0140-6736(06)68304-9
  • De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, Farley MM, Harrison LH, Lynfield R, Bennett NM, et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine 2012; 30:4067-72; PMID:22525797; http://dx.doi.org/10.1016/j.vaccine.2012.04.017
  • Turula V. Application of SEC-MALLS from vaccine development to commercial manufacturing, a paper presented at the 18th Annual Wyatt Technology International Light Scattering Colloquium, Santa Barbara, CA, 16-17 Oct 2006.
  • Rocklin RD, Clarke AP, Weitzhandler M. Improved long-term reproducibility for pulsed amperometric detection of carbohydrates via a new quadruple-potential waveform. Anal Chem 1998; 70:1496-501; http://dx.doi.org/10.1021/ac970906w